Hong Kong Stock Movement
Stocks with High Trading Volume in the Industry
China National Pharmaceutical Group rose 0.27%. Based on recent important news:
<ol>
<li>
On September 15, Citic Lyon released a report stating that although China National Pharmaceutical Group did not turn a profit in the first half of the year, it holds a structurally optimistic view of the industry, raising the target price to HKD 24.5 and maintaining the rating of &#34;outperform,&#34; which drove the stock price up.
</li>
<li>
On September 16, China National Pharmaceutical International plans to increase its investment in Luzhong Investment, indirectly controlling Shandong Pharmaceutical Glass Co., Ltd. The asset adjustment is related to policies, driving stock price fluctuations.
</li>
<li>
On September 15, the Lyon report pointed out that the relaxation of medical insurance expenditures and the domestic interest rate reduction cycle help improve distributors' financial leverage, boosting China National Pharmaceutical Group's stock price. The pharmaceutical industry's policy optimization has led to significant capital inflows.
</li>
</ol>
Shanghai Pharmaceuticals rose 0.49%, with a trading volume of HKD 45.88 million. Based on recent important news:
<ol>
<li>
On September 15, Shanghai Pharmaceuticals' major shareholder, Shanghai Pharmaceutical Group, plans to increase its holdings of the company's H shares through its wholly-owned subsidiary, Shanghai International, within the next 12 months, increasing the total number of shares from 55 million to 74 million, accounting for 2% of the company's voting shares. This news boosted market confidence, driving the stock price up.
</li>
<li>
On September 15, Shanghai Pharmaceuticals announced that Shanghai International increased its holdings by 100,000 H shares, bringing its total to 301 million H shares, accounting for 8.104% of the company's total share capital. This move further enhanced investors' confidence in the company's future development, leading to a rise in stock price.
</li>
<li>
On September 17, Shanghai Pharmaceuticals announced that its R&amp;D investment for the first half of 2025 reached RMB 1.148 billion, accounting for 9.44% of the pharmaceutical industry's sales revenue. Continuous R&amp;D investment and a robust dividend policy demonstrate the company's commitment to innovation and shareholder returns, further supporting the rise in stock price. The overall outlook for the pharmaceutical industry is optimistic, with relaxed medical insurance expenditures.
</li>
</ol>
Stocks with High Market Capitalization in the Industry
Baiyunshan fell 0.11%. Based on recent important news:
<ol>
<li>
On September 15, Baiyunshan Pharmaceutical's research and development of the selective RET small molecule inhibitor BYS10 received feedback from the National Medical Products Administration's Drug Evaluation Center, which agreed to apply for market listing using a Phase II single-arm clinical trial in the future. This news put some pressure on the company's stock price, as the market is cautious about the uncertainties in new drug development.
</li>
<li>
On September 16, Baiyunshan Pharmaceutical received approval notices for supplementary applications for various drugs. Although this has no significant impact on the company's current performance, it helps enhance the market competitiveness of its products.
</li>
<li>
On September 15, the R&amp;D expenses for BYS10 have reached RMB 146 million, which will not have a significant impact on the company's financial situation in the short term, but the market is cautious about the increase in subsequent R&amp;D expenses. The uncertainty in innovative drug development is high, requiring caution
</li>
</ol>

00574

PASHUN INT'L fell 22.54%; Sinopharm Holdings rose 0.27%, with a transaction volume of HKD 47.13 million; Shanghai Pharmaceuticals rose 0.49%, with a transaction volume of HKD 45.88 million; Yaoshi Bang fell 1.80%, with a transaction volume of HKD 36.61 million; Baiyunshan fell 0.11%, with a market value of HKD 30.2 billion

Hong Kong stock movement: PASHUN INT'L plummets 22.54%